Mütherig Anke, Scheffler Gesine, Schuler Ulrich S
Palliativ-Zentrum, Universitätsklinikum Carl Gustav Carus Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland.
Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland.
Urologie. 2024 May;63(5):497-506. doi: 10.1007/s00120-024-02347-x.
Pharmacological pain therapy in cancer patients is based on guideline recommendations, which, however, do not fully coincide in all aspects due to varying weighting of evidence. The present article discusses current issues including the decreasing significance of the World Health Organization (WHO) analgesic ladder, with its distinction between step 2 and 3 being increasingly questioned. Risks of nonopioid analgesics such as paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs), particularly in older populations, are discussed. Paracetamol may potentially reduce the effectiveness of immunotherapies. Aspects of administering analgesics via a feeding tube are considered. Recommendations for the treatment of episodic pain, transitioning between different opioids, and some relevant interactions are also discussed.
癌症患者的药物性疼痛治疗基于指南建议,但由于证据权重不同,这些建议在所有方面并不完全一致。本文讨论了当前的一些问题,包括世界卫生组织(WHO)镇痛阶梯的重要性日益降低,其第二步和第三步的区分越来越受到质疑。还讨论了对乙酰氨基酚和非甾体抗炎药(NSAIDs)等非阿片类镇痛药的风险,尤其是在老年人群中的风险。对乙酰氨基酚可能会降低免疫疗法的有效性。文中还考虑了通过饲管给药的相关问题。此外,还讨论了发作性疼痛的治疗建议、不同阿片类药物之间的转换以及一些相关的相互作用。